Navigation Links
Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimer's Disease in MedPredict Report
Date:6/17/2008

SCOTTSDALE, Ariz., June 17 /PRNewswire/ -- MedPredict has published a new report designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. The report, entitled "Thought Leader Insight & Analysis: Alzheimer's Disease," is based on in-depth interviews conducted with a panel of physician thought leaders actively involved in ongoing research.

"There is some real progress being made in development of diagnostics and treatments for Alzheimer's disease," said Dr. Jeffrey Berk, the primary author of this report. "Today's announcement by Wyeth and Elan revealing clinically meaningful results in their Phase II trial of bapineuzumab underscores that progress. Our Thought Leader Panel is excited about the potential for bapineuzumab, and this report provides their interpretation of the trial results and how they might impact ongoing research."

Each panelist offers his perspective on those agents and mechanisms that have the strongest data supporting them, and comments on those where the excitement extends beyond the clinical evidence. These include ARBs, acetylcholinesterase (butyrylcholinesterase) inhibitors, NMDA, M1, 5-HT, alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), anti-TNF and more.

With regard to diagnostics, "We expect demand for diagnostics is going to skyrocket in concert with approvals of agents that alter the course of the disease," continued Dr. Berk. "Our panelists are most excited about amyloid imaging using a tracer chemical called PIB."

Companies mentioned in this report: GE Healthcare, Avid, Bayer Schering, Siemens, C2N Diagnostics, Satoris, Novartis, Forest, Merz, Lundbeck, Daiichi Sankyo, Medivation, Abbott, AstraZeneca, Targacept, Roche, Memory, EnVivo, Wyeth, Epix, GlaxoSmithKline, Merck, Takeda, Sanofi-Aventis, Bristol Myers Squibb, Boehringer Ingelheim, Baxter, Lilly, Intellect Neurosciences, Elan, Myriad, AC Immune, Genentech, Affiris, TransTec, Pfizer, TorreyPines, Transition Therapeutics, Neurochem.

The full report can be purchased by contacting MedPredict at http://www.medpredict.com.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DuPont Leaders Brief Investors on Agriculture Businesses
2. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
3. Aware Celebrates Fifteen Years of Innovation and Leadership in the Biometrics Industry
4. KGI and Smith College Establish Leadership Forum for Women in Bioscience
5. RF Pain Management Industry Leaders Cotop International and NeuroTherm, Inc. Agree to Merge
6. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
7. Assay Designs(TM) Announces Additions to the Leadership Team
8. Deloitte Leadership Offers Crucial Convergence Considerations for Life Sciences Companies
9. 2007 Global Survey Identifies Characteristics of Supply Chain Leaders
10. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala
11. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017 After spending the past two years ... crowdsourced data collection, GeneFo now offers this platform to healthcare stakeholders ... amplifying support, adherence, and data collection vis a vis their members, ... the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics , a ... announces the launch of the new NHS Agile biosensor chip . The ... for a wide range of molecules, including small and large molecules, peptides, proteins, ...
(Date:8/15/2017)... Boston, MA (PRWEB) , ... August 15, 2017 , ... ... unmet need that has compromised these disciplines for more than half a century. ... cannot be counted. It is widely known that molecular tags developed for this ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and ... (IO360°) programming through a series of upcoming panels and events. The partnership culminates with ... The Roosevelt Hotel in New York City. , “With our experience in producing the ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):